NCT04659551View on ClinicalTrials.gov

Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

October 5, 2017

Primary Completion Date

May 25, 2020

Study Completion Date

May 25, 2020

Conditions
Breast Cancer
Interventions
DRUG

Epirubicin

Epirubicin 90 mg/mq i.v. every 3 weeks for three cycles

DRUG

Cyclophosphamide

Cyclophosphamid 600 mg/mq i.v. every 3 weeks for three cycles

DRUG

Triptorelin

Triptorelin 3.75 mg i.m. every 4 weeks until surgery

DRUG

Exemestane

Exemestane 25 mg oral continuous daily dose until surgery

DRUG

Nivolumab

Nivolumab 240 mg flat dose i.v. every two weeks for 8 cycles

Trial Locations (5)

35128

Istituto Oncologico veneto IRCCS, Padua

43126

Azienda Ospedaliera Universitaria di Parma, Parma

Unknown

Arcispedale S. Anna, Cona

Centro di Riferimento Oncologico di Aviano (CRO), Aviano

Arcispedale S. Maria Nuova, Reggio Emilia

All Listed Sponsors
collaborator

University of Padova

OTHER

lead

Istituto Oncologico Veneto IRCCS

OTHER

NCT04659551 - Neoadjuvant Chemo-endocrine Therapy and Immunotherapy for Pre-menopausal Luminal B Breast Cancer Patients | Biotech Hunter | Biotech Hunter